Tubulis enters into collaboration with Gilead Sciences
The agreement, valued at up to $415 million, combines Gilead's long-standing expertise with Tubulis' innovative technology to advance ADC treatment for solid tumors.
News
Thermosome presents encouraging first clinical data
Phase I Trial data show safety and potential efficacy in heavily pre-treated soft tissue sarcoma patients. In 4 out of 6 patients, the disease remained stable per RECIST.
Initial Investment in Lymphatica
OCCIDENT participates in the € 17.9 million Series B funding round of Lausanne-based Lymphatica Medtech that develops novel treatment options for patients …
Tubulis Receives FDA Fast Track Designation
Tubulis' TUB-040, an ADC for platinum-resistant ovarian cancer, receives FDA Fast Track, expediting its development in Phase I/IIa trials to address urgent cancer treatment needs.
Tubulis Doses First Patient in Phase I/IIa Trial for TUB-040
UB-040 targets an overexpressed antigen in ovarian and lung adenocarcinoma. The trial will enroll up to 140 patients across the US, UK, and Europe.
Avelo collaborates with global health leaders in project “BreathForDiagnosis”
The €3 million research project is funded by the European Commission under "Horizon Europe", and co-funded by the Swiss State Secretariat for Education, Research and Innovation (SERI).
Follow-on investment in hemotune
Successful closing of the CHF 14 million Series B2 of hemotune under the lead of Belmondo and with the participation of OCCIDENT, as well as existing and new investors.
Resistell is publishing in Nature!
A peer-reviewed article on Resistell's rapid phenotypic solution for antibiotic susceptibility testing (AST) has been published in Nature Communications.
Follow-on investment in Tubulis
OCCIDENT is excited to announce its participation in Tubulis' €128 million Series B2 round co-led by EQT Life Sciences and Nextech Invest.